Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
about
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody.Lipid raft: A floating island of death or survivalCo-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.MS4A1 dysregulation in asbestos-related lung squamous cell carcinoma is due to CD20 stromal lymphocyte expression.Treating human autoimmune disease by depleting B cellsNovel antibodies as anticancer agents.Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines.Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.Improvement of refractory rheumatoid arthritis after depletion of B cells.Low number of memory B cells in the salivary glands of patients with primary Sjögren's syndrome.
P2860
Q24817041-F13F3B2D-5DBD-4C71-987F-340981111056Q26998351-AE830191-EC13-49C7-8A27-0172F8D739B4Q34237712-B6E212A7-82AC-4B7C-9E85-487B73717C79Q34238810-0D7FC120-6899-45E2-9E88-E6E452AAC20CQ34848963-9F77DAF2-B85C-4D82-9C43-6163EAE92E86Q36832141-41EB1203-5C81-4854-B2C1-4F6C4557CA03Q37060528-34E4CD43-0FAA-40EE-82FB-3704672B4EBEQ38453207-BFD51350-C668-41CD-9DD2-06C71CC86935Q39771415-4A7E624F-F7E1-421D-AB18-F02EA3CC2065Q39944187-927152B0-7ACB-4E01-9A92-F6B0E0E10330Q40454662-8ACCFEAA-B6BD-427D-9969-4137F22386F2Q40696514-D1C54A1C-79D4-4C33-A6BA-6E1CF5F30E60Q47430048-0A1D529A-9B7B-4453-BD4B-6F7FE05F78C9Q50944740-A262FF0F-230A-4A97-80EC-8A25AE36C5B0
P2860
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@ast
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@en
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@nl
type
label
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@ast
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@en
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@nl
prefLabel
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@ast
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@en
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@nl
P2093
P1476
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
@en
P2093
Casolari B
Federico M
P356
10.1016/S1040-8428(00)00069-X
P577
2001-01-01T00:00:00Z